These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37587857)
1. Alteration of tumor suppressors changes the endometrial tumor spectrum. Mayo LD EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857 [TBL] [Abstract][Full Text] [Related]
2. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025 [TBL] [Abstract][Full Text] [Related]
3. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib. Urick ME; Bell DW Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728 [TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target. Urick ME; Bell DW Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
6. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis. Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076 [TBL] [Abstract][Full Text] [Related]
8. FBXW7: a critical tumor suppressor of human cancers. Yeh CH; Bellon M; Nicot C Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763 [TBL] [Abstract][Full Text] [Related]
9. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues. Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486 [TBL] [Abstract][Full Text] [Related]
10. Recent insight into the role of FBXW7 as a tumor suppressor. Yumimoto K; Nakayama KI Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998 [TBL] [Abstract][Full Text] [Related]
12. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels. Urick ME; Yu EJ; Bell DW Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388 [TBL] [Abstract][Full Text] [Related]
13. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304 [TBL] [Abstract][Full Text] [Related]
14. Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland. Onoyama I; Nakayama S; Shimizu H; Nakayama KI Cancer Res; 2020 Dec; 80(24):5515-5530. PubMed ID: 33234509 [TBL] [Abstract][Full Text] [Related]
15. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729 [TBL] [Abstract][Full Text] [Related]
16. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Catasus L; Gallardo A; Cuatrecasas M; Prat J Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438 [TBL] [Abstract][Full Text] [Related]
17. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303 [TBL] [Abstract][Full Text] [Related]
18. Coordination-driven FBXW7 DNAzyme-Fe nanoassembly enables a binary switch of breast cancer cell cycle checkpoint responses for enhanced ferroptosis-radiotherapy. Yu J; Zhang Y; Li L; Xiang Y; Yao X; Zhao Y; Cai K; Li M; Li Z; Luo Z Acta Biomater; 2023 Oct; 169():434-450. PubMed ID: 37516418 [TBL] [Abstract][Full Text] [Related]
19. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687 [TBL] [Abstract][Full Text] [Related]
20. The Role of FBXW7 in Gynecologic Malignancies. Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J Cells; 2023 May; 12(10):. PubMed ID: 37408248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]